{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-26-002072","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.370252+00:00","generated_at":"2026-05-15T17:14:21.195047+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tenax Therapeutics reports Q4/FY2025 loss; LEVEL study fully enrolled, topline Q3 2026","bullets":["Achieved 230-patient randomization target in Phase 3 LEVEL study; topline data expected Q3 2026.","Cash and equivalents $97.6M as of Dec 31, 2025; expected to fund operations through 2027.","Full-year 2025 net loss $52.6M vs $17.6M in 2024; R&D spend $32.7M on trial expansion.","Initiated global Phase 3 LEVEL-2 trial and open-label extension for TNX-103 (levosimendan) in PH-HFpEF.","USPTO issued Notice of Allowance for subcutaneous levosimendan formulation in broad indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-26-002072","json":"https://secwatch.observer/filing/0001654954-26-002072.json","markdown":"https://secwatch.observer/filing/0001654954-26-002072.md","text":"https://secwatch.observer/filing/0001654954-26-002072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495426002072/0001654954-26-002072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495426002072/tennx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:14:21.195047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80046977517a9f33cb6a53105de305a3ef79ac33","claim":"TENAX THERAPEUTICS, INC. reported year ended December 31, 2025 results: net income net loss of $52.6 million.","evidence_excerpt":"Tenax Therapeutics reported a net loss of $52.6 million for the year ended December 31, 2025, compared to a net loss of $17.6 million for the year ended December 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495426002072/0001654954-26-002072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2025"},{"label":"Net income","value":"net loss of $52.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"dd2b9ad8160cd3d20d65f22d2fc999074e5d6838","claim":"TENAX THERAPEUTICS, INC. reported fourth quarter ended December 31, 2025 results: net income net loss of $15.5 million.","evidence_excerpt":"Tenax Therapeutics reported a net loss of $15.5 million for the fourth quarter of 2025, compared to a net loss of $6.3 million for the fourth quarter of 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495426002072/0001654954-26-002072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2025"},{"label":"Net income","value":"net loss of $15.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}